Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma

被引:2
作者
Nakagawa, Saki [1 ,2 ]
Miyashita, Minoru [1 ]
Maeda, Ichiro [3 ,4 ,5 ]
Goda, Atsushi [5 ]
Tada, Hiroshi [1 ]
Amari, Masakazu [6 ]
Kojima, Yasuyuki [7 ]
Tsugawa, Koichiro [7 ]
Ohi, Yasuyo [8 ]
Sagara, Yasuaki [9 ]
Sato, Miku [1 ]
Ebata, Akiko [1 ]
Harada-Shoji, Narumi [1 ]
Suzuki, Takashi [10 ]
Nakanishi, Makoto [11 ]
Ohta, Tomohiko [12 ]
Ishida, Takanori [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Breast & Endocrine Surg Oncol, 1-1 Seiryo-Machi,Aoba Ku, Sendai 9808574, Japan
[2] Osaki Citizen Hosp, Dept Breast Surg, Osaki, Japan
[3] Kitasato Univ, Kitasato Inst Hosp, Dept Pathol, Tokyo, Japan
[4] Kitasato Univ, Dept Pathol, Sch Med, Sagamihara, Japan
[5] St Marianna Univ, Dept Pathol, Sch Med, Kawasaki, Japan
[6] Tohoku Kosai Hosp, Dept Breast Surg, Sendai, Japan
[7] St Marianna Univ, Dept Breast & Endocrine Surg, Sch Med, Kawasaki, Japan
[8] Hakuaikai Sagara Hosp, Dept Pathol, Kagoshima, Japan
[9] Hakuaikai Sagara Hosp, Dept Breast Surg Oncol, Kagoshima, Japan
[10] Tohoku Univ Hosp, Dept Pathol, Sendai, Japan
[11] Univ Tokyo, Inst Med Sci, Div Canc Cell Biol, Tokyo, Japan
[12] St Marianna Univ, Dept Translat Oncol, Grad Sch Med, Kawasaki, Japan
基金
日本学术振兴会;
关键词
F-box protein 22 (Fbxo22); Breast cancer (BC); Invasive lobular carcinoma (ILC); Endocrine therapy; Resistance; Tamoxifen; TAMOXIFEN;
D O I
10.1007/s10549-023-07209-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Invasive lobular carcinoma (ILC) is distinct from invasive ductal carcinoma (IDC) in terms of their hormonal microenvironments that may require different therapeutic strategies. We previously reported that selective estrogen receptor modulator (SERM) function requires F-box protein 22 (Fbxo22). Here, we investigated the role of Fbxo22 as a potential biomarker contributing to the resistance to endocrine therapy in ILC.Methods A total of 302 breast cancer (BC) patients including 150 ILC were recruited in the study. Fbxo22 expression and clinical information were analyzed to elucidate whether Fbxo22 negativity could be a prognostic factor or there were any correlations among clinical variables and SERM efficacy.Results Fbxo22 negativity was significantly higher in ILC compared with IDC (58.0% vs. 27.0%, P < 0.001) and higher in postmenopausal patients than premenopausal patients (64.1% vs. 48.2%, P = 0.041). In the ILC cohort, Fbxo22-negative patients had poorer overall survival (OS) than Fbxo22-positive patients, with 10-year OS rates of 77.4% vs. 93.6% (P = 0.055). All patients treated with SERMs, Fbxo22 negativity resulted in a poorer outcome, with 10-year OS rates of 81.3% vs. 92.3% (P = 0.032). In multivariate analysis regarding recurrence-free survival (RFS) in ILC patients, Fbxo22 status was independently predictive of survival as well as lymph node metastasis.Conclusion Fbxo22 negativity significantly impacts on survival in BC patients with IDC and ILC, and the disadvantage was enhanced among ILC postmenopausal women or patients treated with SERMs. The findings suggest that different therapeutic strategies might be needed according to the different histopathological types when considering adjuvant endocrine therapy.
引用
收藏
页码:453 / 463
页数:11
相关论文
共 50 条
  • [41] Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer
    Penney, Rosalind Brigham
    Roy, Deodutta
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1836 (01): : 60 - 79
  • [42] Lack of Knowledge of Hormone Receptor Status and Use of Endocrine Therapy in Invasive Breast Cancer
    Bell, Robin J.
    Lijovic, Marijana
    Fradkin, Pam
    Bradbury, Jo
    La China, Maria
    Schwarz, Max
    Wolfe, Rory
    Farrugia, Helen
    Davis, Susan R.
    JOURNAL OF WOMENS HEALTH, 2009, 18 (12) : 1975 - 1980
  • [43] Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem
    Luqmani, Yunus A.
    Alam-Eldin, Nada
    MEDICAL PRINCIPLES AND PRACTICE, 2016, 25 : 28 - 40
  • [44] The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 189 - 190
  • [45] Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
    Houston, SJ
    Plunkett, TA
    Barnes, DM
    Smith, P
    Rubens, RD
    Miles, DW
    BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) : 1220 - 1226
  • [46] Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
    S J Houston
    T A Plunkett
    D M Barnes
    P Smith
    R D Rubens
    D W Miles
    British Journal of Cancer, 1999, 79 : 1220 - 1226
  • [47] WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines
    Matthew J. Sikora
    Britta M. Jacobsen
    Kevin Levine
    Jian Chen
    Nancy E. Davidson
    Adrian V. Lee
    Caroline M. Alexander
    Steffi Oesterreich
    Breast Cancer Research, 18
  • [48] Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - A TEAM study analysis
    van de Water, Willemien
    Fontein, Duveken B. Y.
    van Nes, Johanna G. H.
    Bartlett, John M. S.
    Hille, Elysee T. M.
    Putter, Hein
    Robson, Tammy
    Liefers, Gerrit-Jan
    Roumen, Rudi M. H.
    Seynaeve, Caroline
    Dirix, Luc Y.
    Paridaens, Robert
    Kranenbarg, Elma Meershoek-Klein
    Nortier, Johan W. R.
    van de Velde, Cornelis J. H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 297 - 304
  • [49] Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
    Jeffreys, Sarah A.
    Powter, Branka
    Balakrishnar, Bavanthi
    Mok, Kelly
    Soon, Patsy
    Franken, Andre
    Neubauer, Hans
    de Souza, Paul
    Becker, Therese M.
    CELLS, 2020, 9 (09) : 1 - 23
  • [50] The Current Role of Endocrine Therapy in Locally Advanced Breast Cancer to Improve Breast Conservation Rates
    Monnier, Sindy
    Zakhireh, Jennifer
    Esserman, Laura J.
    CURRENT BREAST CANCER REPORTS, 2012, 4 (02) : 139 - 147